Skip to main content
SpringerLink
Log in

Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Morphine and other opioids increase tone and reduce propulsive motility in several segments of the gut, enhance absorption of fluids, and inhibit secretion. This opioid-induced bowel dysfunction may present as infrequent stools, hard stools, difficult defecation, bloating, and sense of incomplete emptying of the bowels, but also dry mouth, gastroesophageal reflux, epigastric fullness, and abdominal cramping. It afflicts about one-third of patients on opioid treatment. Lifestyle measures, such as regular toilet visits, physical activity, and fiber-rich diet, are very unlikely to be successful. Laxatives, such as bisacodyl, sodium picosulfate, sennosides, macrogols, and prucalopride, may relieve opioid-induced constipation (OIC) in a proportion of patients only. A new approach to counteract OIC is the coadministration of an opioid antagonist devoid of the potential to penetrate the brain. In the EU, an oxycodonenaloxone combination has been approved for this purpose. Both components are included in an oral extended-release preparation. Following its release, naloxone acts locally on the gut and antagonizes the inhibitory effect of the opioid. After being absorbed in parallel with oxycodone, naloxone is rapidly and completely inactivated by a high first-pass effect in the liver. In a 2:1 dose ratio it may improve OIC without interfering with the analgesic effect.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. De Schepper HU, Cremonini F, Park MI, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil. 2004;16:383–394.

    Article  PubMed  Google Scholar 

  2. Pasternak GW. Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol. 1993;16:1–18.

    Article  CAS  PubMed  Google Scholar 

  3. Murphy DB, Sutton JA, Prescott LF, Murphy MB. Opioid induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology. 1997;87:765–770.

    Article  CAS  PubMed  Google Scholar 

  4. Smith KJ, Hopp M, Mundin G, Bond S, Connor A. Oxycodone/Naloxone prolonged release tablets reduce oxycodone-induced prolongation of gastrointestinal transit. 5th World Congress of the World Institute of Pain, New York, NY, USA; March 13–16, 2009.

  5. Kaufman PN, Krevsky B, Malmud LS, et al. Role of opiate receptors in the regulation of colonic transit. Gastroenterology. 1988;94:1351–1356.

    CAS  PubMed  Google Scholar 

  6. Shook J, Pelton JP, Hruby VJ, Burks TF. Peptide opioid antagonist separates peripheral and central opioid antitransit effects. J Pharmacol Exp Ther. 1987;243:492–500.

    CAS  PubMed  Google Scholar 

  7. Longstreth G, Thompson W, Chey W, Houghton L, Mearin F, Spiller R. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491.

    Article  PubMed  Google Scholar 

  8. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10:35–42.

    Article  PubMed  Google Scholar 

  9. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther. 2005;7:R1046–1051.

    Article  CAS  PubMed  Google Scholar 

  10. Puxty JAH, Fox RA. Golytely: a new approach to faecal impaction in old age. Age Ageing. 1986;15:182–184.

    Article  CAS  PubMed  Google Scholar 

  11. Cook SF, Lanza L, Zhou X, et al. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008;27:1224–1232.

    Article  CAS  PubMed  Google Scholar 

  12. Allan L, Richarz U, Simpson K, Slappendel R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naıve patients with chronic low back pain. Spine. 2005;30:2484–2490.

    Article  PubMed  Google Scholar 

  13. Davies EC, Green CF, Mottram DR, Pirmohamed M. The use of opioids and laxatives, and incidence of constipation, in patients requiring neck-of-femur (NOF) surgery: a pilot study. J Clin Pharm Ther. 2008;33:561–566.

    Article  CAS  PubMed  Google Scholar 

  14. Droney J, Ross J, Gretton S, Welsh K, Sato H, Riley J. Constipation in cancer patients on morphine. Support Care Cancer. 2008;16:453–459.

    Article  PubMed  Google Scholar 

  15. Hale M, Tudor IC, Khanna S, Thipphawong J. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis. Clin Ther. 2007;29:874–888.

    Article  CAS  PubMed  Google Scholar 

  16. Hale ME, Ahdieh H, Ma T, Rauck R; Oxymorphone ER Study Group 1. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain. 2007;8:175–184.

    Article  CAS  PubMed  Google Scholar 

  17. Kress HG, Von der Laage D, Hoerauf KH, et al. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain. J Pain Symptom Manage. 2008;36:268–779.

    Article  PubMed  Google Scholar 

  18. Marco CA, Plewa MC, Buderer N, Black C, Roberts A. Comparison of oxycodone and hydrocodone for the treatment of acute pain associated with fractures: a double-blind, randomized, controlled trial. Acad Emerg Med. 2005;12:282–288.

    Article  PubMed  Google Scholar 

  19. Matsumoto AK, Babul N, Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med. 2005;6:357–366.

    Article  PubMed  Google Scholar 

  20. Portenoy RK, Farrar JT, Backonja MM, et al. Longterm use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain. 2007;23:287–299.

    Article  PubMed  Google Scholar 

  21. Staats PS, Markowitz J, Schein J. Incidence of constipation associated with longacting opioid therapy: A comparative study. South Med Journal. 2004;97:129–134.

    Article  Google Scholar 

  22. Tuteja AK, Biskupiak J, Stoddard GJ, Lipman AG. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil. 2010;22:424–430.

    Article  CAS  PubMed  Google Scholar 

  23. Weinstein SM, Shi M, Buckley BJ, Kwarcinski MA. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain. Clin Ther. 2006;28:86–98.

    Article  CAS  PubMed  Google Scholar 

  24. Wirz S, Wittmann M, Schenk M, et al. Gastrointestinal symptoms under opioid therapy: A prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain. 2009;13:737–743.

    Article  CAS  PubMed  Google Scholar 

  25. Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61:1181–1187.

    Article  CAS  PubMed  Google Scholar 

  26. Pappagallo, M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(5A Suppl.):11S–18S.

    Article  Google Scholar 

  27. Bouvy M L, Buurma H, Egberts TCG. Laxative prescribing in relation to opioid use and the influence of pharmacy-based intervention. J Clin Pharm Ther. 2002;27;107–110.

    Article  CAS  PubMed  Google Scholar 

  28. Thomas J. Opioid-induced bowel dysfunction. J Pain Symptom Manage. 2008;35:103–113.

    Article  CAS  PubMed  Google Scholar 

  29. Freedman MD, Schwartz HJ, Roby R, Fleisher S. Tolerance and efficacy of polyethylene glycol 3350/electrolyte solution versus lactulose in relieving opiate induced constipation: a double-blinded placebo-controlled trial. J Clin Pharmacol. 1997;37:904–907.

    CAS  PubMed  Google Scholar 

  30. Hawley PH, Byeon JJ. A comparison of sennosides-based bowel protocols with and without docusate in hospitalized patients with cancer. J Pall Med. 2008;11:575–581.

    Article  Google Scholar 

  31. Moulin DE, Rykx A, Kerstens R, Vandenplassche L. Randomized double-blind placebo-controlled trial to evaluate efficacy and safety of prucalopride (Resolor) in patients with opioid-induced constipation. Gastroenterol. 2008;134:A92.

    Google Scholar 

  32. Olsen O, Håkansson T, Forrest JI. Bisocadyl in the treatment of postoperative intestinal atony. Ugeskr Laeger. 1985;147:3070–3071.

    CAS  PubMed  Google Scholar 

  33. McNicol E, Boyce DB, Schumann R, Carr D. Efficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials. Pain Med. 2008;9:634–659.

    Article  PubMed  Google Scholar 

  34. Chamberlain BH, Cross K, Winston JL, et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. J Pain Symptom Manage. 2009;38:683–690.

    Article  CAS  PubMed  Google Scholar 

  35. Slatkin N, Thomas JT, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009;7:39–46.

    CAS  PubMed  Google Scholar 

  36. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008:358:2332–2343.

    Article  CAS  PubMed  Google Scholar 

  37. Büchler MW, Seiler CM, Monson JR, et al. Clinical trial: alvimopan for the management of postoperative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study. Aliment Pharmacol Ther. 2008;28:312–325.

    Article  PubMed  Google Scholar 

  38. Ludwig K, Enker WE, Delaney CP, et al. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. Arch Surg. 2008;143:1098–1105.

    Article  CAS  PubMed  Google Scholar 

  39. Wolff BG, Michelassi F, Gerkin TM, et al. Alvimopan, a novel, peripherally acting opioid antagonist. Ann Surg. 2004;240:728–735.

    PubMed  Google Scholar 

  40. Leow KP, Smith MT, Williams B, Cramond T. Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther. 1992;52:487–495.

    Article  CAS  PubMed  Google Scholar 

  41. Reder RF, Oshlack B, Miotto JB, Benziger DD, Kaiko RF. Steady-state bioavailability of controlled-release oxycodone in normal subjects. Clin Ther. 1996;18:95–105.

    Article  CAS  PubMed  Google Scholar 

  42. Colucci RD, Swanton RE, Thomas GB, Kaiko RF. Relative variability in bioavailability of oral controlled-release formulations of oxycodone and morphine. Am J Ther. 2001;8:231–236.

    Article  CAS  PubMed  Google Scholar 

  43. Mucci-LoRusso P, Berman BS. Silberstein PT, et al. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, paraIlel-group study. Eur J Pain. 1998;2:233–249.

    Article  Google Scholar 

  44. Fishman J, Roffwarg H, Hellman L. Disposition of naloxone-7,8-3H in normal and narcotic dependent men. J Pharmacol Exp Ther. 1973;187:575–580.

    CAS  PubMed  Google Scholar 

  45. Weinstein SH, Pfeffer M, Schor JM. Metabolism and pharmacokinetics of naloxone. Adv Biochem Psychopharmacol. 1973;8:525–535.

    CAS  PubMed  Google Scholar 

  46. Albeck H, Woodfield S, Kreek MJ. Quantitative and pharmacokinetic analysis of naloxone in plasma using high-performance liquid chromatography with electrochemical detection and solid-phase extraction. J Chromatogr. 1989;488:435–445.

    Article  CAS  PubMed  Google Scholar 

  47. Basilisco G, Camboni G, Bozzani A, Paravicini M, Bianchi PA. Oral naloxone antagonizes loperamide-induced delay of orocecal transit. Dig Dis Sci. 1987;32:829–832.

    Article  CAS  PubMed  Google Scholar 

  48. Hawkes ND, Richardson C, Evans BK, Rhodes J, Lewis SJ, Thomas GA. Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine. Aliment Pharmacol Ther. 2001;15:625–630.

    Article  CAS  PubMed  Google Scholar 

  49. Holzer P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett. 2004;361:192–195.

    Article  CAS  PubMed  Google Scholar 

  50. Kreek MJ, Schaefer RA, Hahn EF, Fishman J. Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation. Lancet. 1983;i:261–262.

    Article  Google Scholar 

  51. Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med. 1996;10:135–144.

    Article  CAS  PubMed  Google Scholar 

  52. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage. 2002;23:48–53.

    Article  PubMed  Google Scholar 

  53. Smith K, Hopp M, Mundin G, et al. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. Clin Ther. 2008;30:2051–2068.

    Article  CAS  PubMed  Google Scholar 

  54. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13:56–64.

    Article  CAS  PubMed  Google Scholar 

  55. Rentz AM, Yu R, Müller-Lissner SA, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ. 2009;12:371–383.

    Article  CAS  PubMed  Google Scholar 

  56. Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate to severe noncancer pain. Curr Med Res Opin. 2008;24:3503–3512.

    Article  CAS  PubMed  Google Scholar 

  57. Löwenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother. 2009;10:531–543.

    Article  PubMed  Google Scholar 

  58. Ballantyne JC, Carwood C. Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer. Cochrane Database Syst Rev. 2005;(2):CD005178.

Download references

Author information

Authors and Affiliations

  1. Park-Klinik Weissensee, Schönstrasse 80, 13086, Berlin, Germany

    Stefan Mueller-Lissner

Authors
  1. Stefan Mueller-Lissner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Mueller-Lissner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mueller-Lissner, S. Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation. Adv Therapy 27, 581–590 (2010). https://doi.org/10.1007/s12325-010-0057-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-010-0057-y

Keywords

Search

Navigation